Summary:
A randomized, placebo-controlled, dose-ranging, multi-centre trial of AZW039 (1-450 mg p.o.) to investigate the effect on FEV1 and ACQ in patients with moderae-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy
Qualified Participants Must:
• Are between 18 and 65 years of age.
Are experiencing asthma symptoms while on a currently prescribed maintenance inhailer.
Have a diagnosis of moderate to severe persistent asthma. Have a history of allergies
Qualified Participants May Receive:
Study-related care, lab tests and study medication will be provided to those who qualify. Compensation for time/travel will be provided